Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether there itraconazole is effective in the treatment of chronic cavitary pulmonary aspergillosis

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Hydroxyitraconazole; Itraconazole

Criteria

1. Inclusion Criteria:

1. Clinical symptoms: -presence of chronic pulmonary/systemic symptoms lasting ≥ six weeks.

2. Radiological findings:

• Evidence of slowly progressive pulmonary lesions over weeks-months including cavities with surrounding inflammation.

• presence of intracavitary mass with a surrounding crescent of air,and presence of pleural thickening in peripheral lesions.

3. Microbiological/Immunological findings: Positive results in the aspergillus precipitin test, demonstration of aspergillus hyphae in sputum or BAL fluid or cultures of BAL/sputum growing aspergillus species.

2. The diagnosis of CCPA will be made if

1. Patient satisfies at least 1, 2a or 2b and/ or any of the 3rd criteria.

2. FNAC from the cavity wall will be considered in atypical cases

3. Exclusion Criteria:

1. Invasive aspergillosis

2. Allergic broncho-pulmonary aspergillosis (ABPA)

3. Active tuberculosis or malignancy

4. Pregnant females